Stephen joined Sygnature in January 2016 from Hitgen where he was VP Business Development; establishing several early research collaborations for this Chinese CRO start-up. Prior to Hitgen he held business development positions at Pharmacia, Novabiochem and Protherics. He is a highly-experienced Medicinal Chemist and has worked in a broad range of therapeutic areas within small and large discovery organisations including MSD, Proteus, Tularik, Amgen and, most recently, Vertex, where he led the Discovery Chemistry department in the UK. Stephen has a BSc (Hons.) in chemistry and a PhD in medicinal chemistry from the University of Nottingham, and undertook post-doctoral research at the University of Edinburgh in the area of peptide synthesis methodology.